252 related articles for article (PubMed ID: 31121062)
1. Clinical outcomes and predictive relapse factors of IgG4-related disease following treatment: a long-term cohort study.
Peng Y; Li JQ; Zhang PP; Zhang X; Peng LY; Chen H; Zhou JX; Zhang SZ; Yang HX; Liu JJ; Guo HF; Li J; Zhang X; Zhao Y; Zeng XF; Zhang FC; Fei YY; Zhang W
J Intern Med; 2019 Nov; 286(5):542-552. PubMed ID: 31121062
[TBL] [Abstract][Full Text] [Related]
2. Failure of remission induction by glucocorticoids alone or in combination with immunosuppressive agents in IgG4-related disease: a prospective study of 215 patients.
Wang L; Zhang P; Wang M; Feng R; Lai Y; Peng L; Fei Y; Zhang X; Zhao Y; Zeng X; Zhang F; Zhang W
Arthritis Res Ther; 2018 Apr; 20(1):65. PubMed ID: 29636109
[TBL] [Abstract][Full Text] [Related]
3. Clinical features and relapse risks factors of IgG4 related disease: a single-center retrospective study.
Zhang X; Zeng Z; Tian H; Wang N; Wang Y; Tong J; Chang B; Jin X; Huang D; Wang Y; Cui H; Guan L; Li Y
Clin Exp Med; 2023 Nov; 23(7):3527-3538. PubMed ID: 37392248
[TBL] [Abstract][Full Text] [Related]
4. Withdrawal of immunosuppressants and low-dose steroids in patients with stable IgG4-RD (WInS IgG4-RD): an investigator-initiated, multicentre, open-label, randomised controlled trial.
Peng L; Nie Y; Zhou J; Wu L; Chen X; Wang F; Li J; Peng Y; Lu H; Zhao L; Li M; Zhao Y; Zeng X; Fei Y; Zhang W
Ann Rheum Dis; 2024 Apr; 83(5):651-660. PubMed ID: 38216319
[TBL] [Abstract][Full Text] [Related]
5. Clinical characteristics and therapeutic response of immunoglobulin G4-related disease: a retrospective study of 127 Chinese patients.
An W; Wu Z; Li M; Yu H; Zhao X; Wang X; Wang Y; Wang Q; Duan W; Kong Y; Ma H; Ou X; You H; Liu Y; Li P; Duan T; Jia J
Orphanet J Rare Dis; 2022 Aug; 17(1):307. PubMed ID: 35927746
[TBL] [Abstract][Full Text] [Related]
6. Relapse predictors and serologically unstable condition of IgG4-related disease: a large Chinese cohort.
Liu Y; Zeng Q; Zhu L; Gao J; Wang Z; Wang Z; Yang F; Wang K; Chen D; Xia C; Zhang S; Wang Y; Shen D; Yu G; Li ZG
Rheumatology (Oxford); 2020 Aug; 59(8):2115-2123. PubMed ID: 32097488
[TBL] [Abstract][Full Text] [Related]
7. Additive effect of leflunomide and glucocorticoids compared with glucocorticoids monotherapy in preventing relapse of IgG4-related disease: A randomized clinical trial.
Wang Y; Zhao Z; Gao D; Wang H; Liao S; Dong C; Luo G; Ji X; Li Y; Wang X; Zhao Y; Li K; Zhang J; Jin J; Zhang Y; Zhu J; Zhang J; Huang F
Semin Arthritis Rheum; 2020 Dec; 50(6):1513-1520. PubMed ID: 32113839
[TBL] [Abstract][Full Text] [Related]
8. Sex disparities in clinical characteristics and prognosis of immunoglobulin G4-related disease: a prospective study of 403 patients.
Wang L; Zhang P; Zhang X; Lin W; Tang H; Li J; Wang M; Liu X; Fei Y; Chen H; Peng L; Zhang L; Lai Y; Zeng X; Li X; Xue H; Zhao Y; Zhang F; Zhang W
Rheumatology (Oxford); 2019 May; 58(5):820-830. PubMed ID: 30561747
[TBL] [Abstract][Full Text] [Related]
9. Prognostic factors in IgG4-related disease: a long-term monocentric Chinese cohort study.
Zongfei J; Lingying M; Lijuan Z; Ying S; Rongyi C; Dongmei L; Xiufang K; Xiaomin D; Lili M; Huiyong C; Lindi J
Clin Rheumatol; 2021 Jun; 40(6):2293-2300. PubMed ID: 33151477
[TBL] [Abstract][Full Text] [Related]
10. Prediction of new organ onset in recurrent immunoglobulin G4-related disease during 10 years of follow-up.
Liu Z; Peng Y; Li J; Lu H; Peng L; Zhou J; Zhou S; Huang C; Wang M; Zhu L; Chen H; Wang L; Fei Y; Zhao Y; Zeng X; Zhang W
J Intern Med; 2022 Jul; 292(1):91-102. PubMed ID: 35419810
[TBL] [Abstract][Full Text] [Related]
11. Risk factors of relapse following glucocorticoid tapering in IgG4-related disease.
Sasaki T; Akiyama M; Kaneko Y; Yasuoka H; Suzuki K; Yamaoka K; Takeuchi T
Clin Exp Rheumatol; 2018; 36 Suppl 112(3):186-189. PubMed ID: 29846165
[TBL] [Abstract][Full Text] [Related]
12. Differences and similarities between IgG4-related disease with and without dacryoadenitis and sialoadenitis: clinical manifestations and treatment efficacy.
Wang M; Zhang P; Lin W; Fei Y; Chen H; Li J; Zhang L; Zheng W; Li Y; Zeng X; Zhou J; Lai Y; Liu X; Xue H; Cui Y; Zhou L; Zhao J; Zhang W
Arthritis Res Ther; 2019 Feb; 21(1):44. PubMed ID: 30709411
[TBL] [Abstract][Full Text] [Related]
13. Treatment of immunoglobulin G4-related sialadenitis: outcomes of glucocorticoid therapy combined with steroid-sparing agents.
Hong X; Zhang YY; Li W; Liu YY; Wang Z; Chen Y; Gao Y; Sun ZP; Peng X; Su JZ; Cai ZG; Zhang L; He J; Ren LM; Yang HY; Li ZG; Yu GY
Arthritis Res Ther; 2018 Jan; 20(1):12. PubMed ID: 29382364
[TBL] [Abstract][Full Text] [Related]
14. Clinical value of plasmablasts in predicting disease relapse in patients with IgG4-related disease.
Wang Y; Zhao Z; Gao D; Wang H; Liao S; Luo G; Ji X; Li Y; Wang X; Zhao Y; Li K; Zhang J; Jin J; Zhang Y; Zhu J; Zhang J; Huang F
Clin Rheumatol; 2023 Jan; 42(1):135-143. PubMed ID: 36074221
[TBL] [Abstract][Full Text] [Related]
15. Rituximab Maintenance Therapy Reduces Rate of Relapse of Pancreaticobiliary Immunoglobulin G4-related Disease.
Majumder S; Mohapatra S; Lennon RJ; Piovezani Ramos G; Postier N; Gleeson FC; Levy MJ; Pearson RK; Petersen BT; Vege SS; Chari ST; Topazian MD; Witzig TE
Clin Gastroenterol Hepatol; 2018 Dec; 16(12):1947-1953. PubMed ID: 29526692
[TBL] [Abstract][Full Text] [Related]
16. Combination therapy of leflunomide and glucocorticoids for the maintenance of remission in patients with IgG4-related disease: a retrospective study and literature review.
Wang Y; Li K; Gao D; Luo G; Zhao Y; Wang X; Zhang J; Jin J; Zhao Z; Yang C; Zhu J; Zhang J; Huang F
Intern Med J; 2017 Jun; 47(6):680-689. PubMed ID: 28321964
[TBL] [Abstract][Full Text] [Related]
17. The Role of Symptom Duration and Serologic Factors in the Relapse of IgG4-Related Ophthalmic Disease following Surgery: A Retrospective Cohort Study.
Liu S; Yue Z; Zeng C; Huang X; Li J; Diao J; Chen X; Wei R; Yang W
Dis Markers; 2022; 2022():5651506. PubMed ID: 35256891
[TBL] [Abstract][Full Text] [Related]
18. Clinical manifestations, clinical course, and outcomes of immunoglobulin G4-related disease.
Phaopraphat K; Ngamjanyaporn P; Narongroeknawin P; Kasitanon N; Katchamart W
Int J Rheum Dis; 2020 Nov; 23(11):1468-1473. PubMed ID: 32808722
[TBL] [Abstract][Full Text] [Related]
19. Glucocorticoids in the treatment of IgG4-related disease-Prospects for new international treatment guidelines.
Yoshifuji H; Umehara H
Mod Rheumatol; 2023 Mar; 33(2):252-257. PubMed ID: 35993488
[TBL] [Abstract][Full Text] [Related]
20. Clinical features and relapse risks of IgG4-related ophthalmic disease: a single-center experience in China.
Zhao Z; Mou D; Wang Z; Zeng Q; Wang Z; Xue J; Ren L; Liu Y; Su Y
Arthritis Res Ther; 2021 Mar; 23(1):98. PubMed ID: 33789746
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
